Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Elecoglipron for weight management in Asian adults with obesity or overweight

Tests elecoglipron against placebo for weight management in Asian adults with obesity or overweight.

Key facts

Who runs it
AstraZeneca
Where
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi, Jincheng, Jinzhou Shi, Langfang, Luoyang, Meihekou, Nanjing, Nanyang, Shanghai, Shantou, Shenyang, Shijiazhuang, Wuhan, Wuhu, Xianyang, Xuzhou, Yan’an, Yueyang, Zhumadian, and Zibo, ChinaSee the 27 sitesAlso in 4 other countries, 17 sites
Trial code
Registry title
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Status
Recruiting
Phase
Phase 3
People taking part
351 people, planned
Started
21 Aug 2026
Expected to end
13 Apr 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Elecoglipron
  • Placebo
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight, with or without type 2 diabetes. It compares elecoglipron with placebo alongside diet and exercise for weight management.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Body mass index (BMI) of 28 kg/m^2 or higher, or 24 kg/m^2 to less than 28 kg/m^2 with at least 1 weight-related comorbidity. People with type 2 diabetes need HbA1c from 6.5% (48 mmol/mol) to less than 10.0% (86 mmol/mol).
Earlier treatment
At least 1 self-reported unsuccessful dietary effort to lose body weight. Stable body weight for 90 days before screening (± 5% change).
Biomarker or test result
HbA1c from 6.5% (48 mmol/mol) to less than 10.0% (86 mmol/mol) at screening, for people with type 2 diabetes.

Main reasons for not taking part

  • Type 1 diabetes
  • HbA1c of 10% (86 mmol/mol) or higher at screening
  • Treatment for diabetic retinopathy or macular edema, now or expected
  • More than one episode of severe hypoglycemia in the 180 days before screening, or hypoglycemia unawareness
  • History of acute or chronic pancreatitis, or of medullary thyroid cancer or multiple endocrine neoplasia type 2 (also in first-degree relatives)

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adult participant aged 18 years or older at the time of informed consent
  • Body mass index (BMI) at screening of:
  • 28 kg/m\^2 or higher, or
  • 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity
  • Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
  • History of at least 1 self-reported unsuccessful dietary effort to lose body weight
  • Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening

Who cannot take part

  • Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
  • History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • Any of the following medical history, laboratory values, or complications related to diabetes:
  • HbA1c ≥ 10% (86 mmol/mol) at the screening visit
  • T1DM

Where in China

Also in 4 other countries, 17 sites

  • BaotouHospital not named in the registryNot yet recruiting
  • BeijingHospital not named in the registryTaking people
  • ChangdeHospital not named in the registryTaking people
  • ChangshaHospital not named in the registryTaking people
  • ChangzhouHospital not named in the registryTaking people
  • ChengduHospital not named in the registryTaking people
  • HefeiHospital not named in the registryTaking people
  • HuangshiHospital not named in the registryTaking people
  • JinchengHospital not named in the registryTaking people
  • Jinzhou ShiHospital not named in the registryNot yet recruiting
  • LangfangHospital not named in the registryTaking people
  • LuoyangHospital not named in the registryNot yet recruiting
  • MeihekouHospital not named in the registryTaking people
  • NanjingHospital not named in the registryTaking people
  • NanyangHospital not named in the registryTaking people
  • ShanghaiHospital not named in the registryTaking people
  • ShantouHospital not named in the registryTaking people
  • ShenyangHospital not named in the registryTaking people
  • ShijiazhuangHospital not named in the registryTaking people
  • WuhanHospital not named in the registryNo longer taking part
  • WuhuHospital not named in the registryTaking people
  • XianyangHospital not named in the registryTaking people
  • XuzhouHospital not named in the registryTaking people
  • Yan’anHospital not named in the registryTaking people
  • YueyangHospital not named in the registryTaking people
  • ZhumadianHospital not named in the registryTaking people
  • ZiboHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

The 3 groups in the trial

  • Arm 1 - Dose 1Treatment being tested

    Active IMP

    Treatment: Elecoglipron

  • Arm 2 - Dose 2Treatment being tested

    Active IMP

    Treatment: Elecoglipron

  • Arm 3 - PlaceboPlacebo, for comparison

    Placebo matching elecoglipron

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)
Plain-language title
Elecoglipron for weight management in Asian adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Record updated
9 November 2026